Search

Your search keyword '"Raoul Muteganya"' showing total 8 results
Start Over Author "Raoul Muteganya"
8 results on '"Raoul Muteganya"'

1. An Exceptional Cause of Increased 18F-Fluorodeoxyglucose Uptake on PET/CT in a Thyroid Nodule

Author

Ringo Manta, Raoul Muteganya, Abraham J. Beun, Jennifer Fallas, and Kris G. Poppe

Subjects
thyroid sarcoidosis, FDG PET/CT, thyroid nodule, Medicine (General), R5-920
Abstract

A 41-year-old female underwent a cervical spine CT for the workup of posterior neck pain irradiating to the shoulders for several months. An incidental thyroid nodule was found and classified as Bethesda III on the Fine-needle aspiration cytology (FNAC) results. Three months later, the patient developed mild shortness of breath, dry cough, and fever. Chest X-ray revealed a mild enlargement in the bilateral hilar regions. CT showed mediastinal and bilateral hilar enlarged lymph nodes and pulmonary micronodules. The workup was further completed with a 18F-FDG PET/CT, showing intense FDG uptake in the mediastinal and bilateral hilar lymph nodes and increased uptake in the thyroid nodule. Endobronchial Ultrasound-guided Transbronchial needle aspiration (EBUS-TBNA) of a left hilar lymph node showed epithelioid non-necrotizing granulomas. Because of the FNAC results, size of the nodule and tracheal shift, thyroid lobectomy was performed one month later. Histopathological results also revealed multiple non-necrotizing epithelioid granulomas, suggesting systemic sarcoidosis with involvement of the thyroid. To our knowledge, this is the first report of thyroid sarcoidosis detected on 18F-FDG PET/CT. Although an increased FDG uptake in a thyroid nodule is usually suggestive of thyroid malignancy, toxic nodule, or follicular hyperplasia, our case report shows that it could also suggest thyroid sarcoidosis.

Published
2023
Full Text
View/download PDF

2. Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review

Author

Raoul Muteganya, Serge Goldman, Fouad Aoun, Thierry Roumeguère, and Simone Albisinni

Subjects
imaging, MRI, lymph nodes, PET, PSMA, prostate cancer, Surgery, RD1-811
Abstract

Introduction: Lymph node metastases (LNM) represent a proven prognostic factor for biochemical recurrence (BCR)-free survival, metastatic free survival and overall survival in prostate cancer (PCa). Although pelvic node dissection remains the gold standard for the detection of LNM, novel imaging techniques are entering clinical practice, in the effort to improve LNM detection and spare unnecessary surgeries. Aim of the current review is to describe such imaging techniques and explore their advantages and limitations.Evidence Acquisition: The National Library of Medicine Database was searched for relevant articles published between January 2013 and August 2018. A wide search was performed including the combination of following words: “Prostate” and “Cancer” and “staging” and “Lymph Node” and “imaging” and (“MRI” or “PET”). The initial list of selected papers was enriched by individual suggestions of the authors of the present review.Evidence Synthesis: DWI-MRI in detection of lymph node invasion has a sensitivity and specificity of 41 and 94%, respectively. For SPIO MRI using ferumoxtran-10, the sensitivity for detection of LNM with short axis diameter of 5–10 mm is reported at 96.4%, compared to 28.5% with MRI alone. PSMA PET/CT is growing exponentially, both in the initial detection of LNM and for BCR evaluation. Fluciclovine PET could improve detection of subcentimetric pathologic lymph nodes. Sentinel lymph node techniques remain experimental and not validated in the field of PCa.Conclusions: Molecular imaging, particularly PSMA ligand PET imaging, present interesting diagnostic accuracy in LN diagnosis even in subcentimetric LN. DWI-MRI yields good results in LN involvement evaluation and the use of contrast agent such SPIO may improve the detection rate. The SLN technique is limited to experimental protocols and for intermediate or high-risk PCa. Prospective trials are awaited to evaluate the true clinical impact of these imaging techniques on PCa oncologic outcomes.

Published
2018
Full Text
View/download PDF

3. The metabolic clinical risk score as a new prognostic model for surgical decision‐making in patients with colorectal liver metastases

Author

Raoul Muteganya, Gaetan Van Simaeys, Celine Mathey, Jonathan Nezri, Serge Goldman, Valerio Lucidi, Desislava Germanova, Hugo Levillain, Ivan Duran Derijckere, Vincent Donckier, Patrick Flamen, Alain Hendlisz, Fikri Bouazza, Nicola Trotta, and Ali Bohlok

Subjects
medicine.medical_specialty, Early Relapse, Computed tomography, 18FDG-PET/CT, Gastroenterology, surgery, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, score, In patient, Chirurgie, medicine.diagnostic_test, business.industry, General Medicine, 18fdg pet ct, Cancérologie, colorectal liver metastases, Oncology, 030220 oncology & carcinogenesis, Prognostic model, 030211 gastroenterology & hepatology, Surgery, business, prognostic, Clinical risk factor
Abstract

Background and Objectives: Selection for surgery in patients with colorectal liver metastases (CRLM) remains inaccurate. We evaluated if CRLM baseline metabolic characteristics, assessed by [18]F-fluorodeoxyglucose-positron emission tomography/computed tomography (18FDG-PET/CT), could predict postoperative outcomes. Methods: In a retrospective series of patients undergoing surgery for CRLM, we defined two groups: the long-term survival (LTS) and early relapse (ER) groups, where the postoperative recurrence-free survivals were ≥5 years or 4.3, defining low- and high-risk mCRS by scores of 0 to 2 and 3 to 6, respectively. Results: From a series of 450 patients operated for CRLM (mean follow-up of 58 months), we included for analysis 23 and 30 patients in the LTS and ER groups, respectively. Clinicopathologic parameters and CRS were similar in the LTS and ER groups. Median SUVmax/SUVmean(liver) ratios were higher in ER vs LTS patients (4.2 and 2.8, P =.008, respectively). mCRS was increased in ER patients (P =.024); 61% of LTS patients had low-risk mCRS and 73% of the ER patients had high-risk mCRS (P =.023). Conclusions: 18FDG-PET/CT characteristics combined with traditional CRS may represent a new tool to improve selection for surgery in patients with CRLM., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2019

4. Imaging for Salvage Therapy in Recurrent Prostate Cancer

Author

Simone Albisinni and Raoul Muteganya

Subjects
Radical treatment, Oncology, Curative intent, medicine.medical_specialty, business.industry, Internal medicine, medicine, Salvage therapy, Recurrent prostate cancer, Disease, business
Abstract

In clinically localized PCa, despite radical treatment with curative intent, up to 50% of patients experience disease recurrence within 10 years. This chapter deals with imaging for Salvage Therapy in Recurrent Prostate Cancer.

Published
2020

5. Failure of Classical β-Blocker Carvedilol to Deactivate Brown Adipose Tissue in a Patient With Pheochromocytoma

Author

Kathleen Weyts, Raoul Muteganya, Serge Goldman, Eva El Darazi, and Ioannis Tsechelidis

Subjects
Adult, medicine.medical_specialty, Adrenergic beta-Antagonists, Urology, Adrenal Gland Neoplasms, Carbazoles, Adrenergic, Adipose tissue, Propranolol, Pheochromocytoma, 030218 nuclear medicine & medical imaging, Propanolamines, 03 medical and health sciences, 0302 clinical medicine, Adipose Tissue, Brown, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Brown adipose tissue, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Treatment Failure, Carvedilol, business.industry, Fdg uptake, General Medicine, medicine.disease, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, business, Diazepam, medicine.drug
Abstract

A 37-year-old woman with pheochromocytoma underwent presurgical FDG PET/CT. Despite her usual antiadrenergic medication consisting in 25 mg of carvedilol, PET/CT demonstrated intense and widespread FDG uptake in brown adipose tissue (BAT). No BAT FDG uptake was detectable on a repeated examination after specific preparation consisting in 40 mg propranolol and 5 mg diazepam. We therefore recommend this propranolol-diazepam preparation in patients with pheochromocytoma referred for PET/CT. Carvedilol-classically prescribed to alleviate effects of adrenergic overstimulation-seems ineffective on BAT. This observation questions the benefit of carvedilol to reduce β3-adrenoreceptor-mediated effects, not only in BAT, but also in other tissues.

Published
2018

6. The metabolic clinical risk score (mCRS) as a new prognostic model for surgical decision in patients with colorectal liver metastases

Author

Valerio Lucidi, Jonathan Nezri, Serge Goldman, Celine Mathey, Ali Bohlok, Raoul Muteganya, Vincent Donckier, Alain Hendlisz, Ivan Duran Derijckere, Patrick Flamen, Hugo Levillain, Gaetan Van Simaeys, and Fikri Bouazza

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Prognostic model, Medicine, In patient, business, Clinical risk factor, Selection (genetic algorithm)
Abstract

e15094 Background: Selection for surgery in patients with colorectal liver metastases (CRLM) remains poorly accurate. We evaluated if baseline metabolic characteristics of CRLM, as assessed by [18]-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (18FDG-PET/CT), may predict the postoperative outcome in patients operated for CRLM. Methods: In a series of 450 patients operated for CRLM, we retrospectively identified 2 groups: The long-term survival (LTS), as defined by postoperative recurrence-free survival (RFS)≥5 years, and the early relapse groups (ER), as defined by RFS < 1 year. Clinicopathologic characteristics, Clinical Risk Score (CRS) and baseline 18FDG-PET/CT metabolic parameters were analyzed. Baseline 18FDG-PET/CT was performed at the time of diagnosis of CRLM, before any preoperative treatment. Low and high-risk CRS were defined by scores of 0 to 2 and 3 to 5, respectively. Metabolic CRS (mCRS) was implemented, using 1 additional point to the standard CRS when the highest tumor standardized uptake value (SUVmax) and normal liver mean SUV (SUVmean(liver)) ratio was > 4.3. Low and high-risk mCRS were defined by scores of 0 to 2 and 3 to 6, respectively. Results: We analyzed 53 patients. No difference was observed between LTS (n = 23) and ER (n = 30) groups for clinicopathologic parameters related to the primary tumor and CRLM, CRS and rates of low/high risk CRS. All metabolic parameters analyzed, including SUVmax and SUVpeak, at the exception of metabolic tumor volume, were significantly increased in ER group. Median SUVmax/SUVmean(liver) ratio was significantly increased in the ER vs LTS, respectively of 4.2 and 2.8 (p = 0.008). mCRS was significantly higher in ER as compared to LTS patients (p = 0.024), while 61% of the LTS patients had a low-risk mCRS and 73% of the ER patients had a high-risk mCRS (p = 0.023). Conclusions: Baseline 18FDG-PET/CT characteristics demonstrate an increased tumor glucose uptake in patients who rapidly recur after curative-intent surgery for CRLM. The introduction of these data into clinical risk model may represent a new tool to improve selection for surgery in patients with CRLM.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results